Grant: Project Grant - PA: Epigenetics/epigenomics in human health or disease
University of Toronto
$100,000.00
Isoform-specific roles of the histone variant macroH2A1 in memory and Alzheimer's disease
FY 2022-23
Summary
Alzheimer's disease (AD) is a debilitating neurodegenerative disease characterized by progressive memory decline. We recently identified histone variants as novel epigenetic regulators of memory that are promising therapeutic targets for memory deficits. Our preliminary data implicate the histone variant mH2A1 as a contributing factor to AD, but the mechanism of its role in normal and deficient memory is unknown. mH2A1 is alternatively spliced into mH2A1.1 and mH2A1.2 isoforms, which have distinct effects on transcription and may play unique roles in memory and AD. Thus, we will investigate splice-isoform specific mechanisms of mH2A1 in normal memory and AD, with a focus on sex differences in mH2A1's role in transcription and behavior. mH2A1.1 is a transcriptional repressor whose depletion impairs memory and elevates transcription through an unknown mechanism. Data from peripheral cells indicate that mH2A1.1 is uniquely able to reduce cellular levels of poly-ADP-ribose (PAR), a post-translational modification that increases transcription. On this basis, we will determine if mH2A1.1 can also inhibit PAR in neurons, if this inhibition underlies the ability of mH2A1.1 to repress transcription, and assess the relevance of this interaction in memory formation. In Aim 2, we will test if mH2A1.1 and mH2A1.2 binding on DNA is altered in AD using brains from human patients and AD model mice. Since mH2A1's effects in AD may be sex specific, we will test if manipulations of mH2A1 expression can improve memory in male and female AD mice and serve as therapeutic targets for memory decline. In Aim 3, we will test the contribution of sex hormones to mH2A1.1 and mH2A1.2 regulation as a critical step for understanding how sex differences in mH2A1 isoforms are established and maintained in health and disease. Together, these studies will introduce mH2A1 isoforms as novel regulators of memory and AD and inform future studies on mH2A1 as a therapeutic target for memory decline.
Department
Program
Project Grant - PA: Epigenetics/epigenomics in human health or disease
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
472567
Name
Zovkic Iva
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Molecular & Cellular Neurosciences - B
Projecttitle
Isoform-specific roles of the histone variant macroH2A1 in memory and Alzheimer's disease
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - PA: Epigenetics/epigenomics in human health or disease
Keyworddelim
Alzheimer'S Disease; Chromatin; Epigenetics; Gene Expression; Histone Variants; Macroh2a1; Memory; Mice
Abstract
Alzheimer's disease (AD) is a debilitating neurodegenerative disease characterized by progressive memory decline. We recently identified histone variants as novel epigenetic regulators of memory that are promising therapeutic targets for memory deficits. Our preliminary data implicate the histone variant mH2A1 as a contributing factor to AD, but the mechanism of its role in normal and deficient memory is unknown. mH2A1 is alternatively spliced into mH2A1.1 and mH2A1.2 isoforms, which have distinct effects on transcription and may play unique roles in memory and AD. Thus, we will investigate splice-isoform specific mechanisms of mH2A1 in normal memory and AD, with a focus on sex differences in mH2A1's role in transcription and behavior. mH2A1.1 is a transcriptional repressor whose depletion impairs memory and elevates transcription through an unknown mechanism. Data from peripheral cells indicate that mH2A1.1 is uniquely able to reduce cellular levels of poly-ADP-ribose (PAR), a post-translational modification that increases transcription. On this basis, we will determine if mH2A1.1 can also inhibit PAR in neurons, if this inhibition underlies the ability of mH2A1.1 to repress transcription, and assess the relevance of this interaction in memory formation. In Aim 2, we will test if mH2A1.1 and mH2A1.2 binding on DNA is altered in AD using brains from human patients and AD model mice. Since mH2A1's effects in AD may be sex specific, we will test if manipulations of mH2A1 expression can improve memory in male and female AD mice and serve as therapeutic targets for memory decline. In Aim 3, we will test the contribution of sex hormones to mH2A1.1 and mH2A1.2 regulation as a critical step for understanding how sex differences in mH2A1 isoforms are established and maintained in health and disease. Together, these studies will introduce mH2A1 isoforms as novel regulators of memory and AD and inform future studies on mH2A1 as a therapeutic target for memory decline.
Competitiondate
202209
Approvedterm2
1 yr 0 mth
Pinamesdelim
Zovkic, Iva
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~